FDA Panel Backs Efficacy Of BioMarin’s Rare Disease Drug Vimizim

Majority of the Endocrinologic and Metabolic Drugs Advisory Committee says effectiveness of elosulfase alfa has been demonstrated and the drug should be approved for all patients with Morquio A syndrome regardless of baseline disease severity.